Docetaxel immunonanocarriers as targeted delivery systems for HER 2-positive tumor cells: preparation, characterization, and cytotoxicity studies
about
RETRACTED: Rituximab-conjugated, doxorubicin-loaded microbubbles as a theranostic modality in B-cell lymphomaDocetaxel Loaded PEG-PLGA Nanoparticles: Optimized Drug Loading, In-vitro Cytotoxicity and In-vivo Antitumor Effect.Folated synperonic-cholesteryl hemisuccinate polymeric micelles for the targeted delivery of docetaxel in melanoma.Fabrication of docetaxel surfaced Fe3O4 magnetite nanoparticles and their cytotoxicity on 4 T1 breast cancer cells.Particle shape enhances specificity of antibody-displaying nanoparticles.Enhanced antibacterial activity of roxithromycin loaded pegylated poly lactide-co-glycolide nanoparticles.Nanomedicine in chemoradiation.Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile.Concepts and practices used to develop functional PLGA-based nanoparticulate systemsNovel targeted siRNA-loaded hybrid nanoparticles: preparation, characterization and in vitro evaluation.Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunitiesCationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted SiRNA Delivery to HER2+ Breast Cancer.Facile production of nanocomposites of carbon nanotubes and polycaprolactone with high aspect ratios with potential applications in drug delivery.Targeted Co-Delivery of Docetaxel and cMET siRNA for Treatment of Mucin1 Overexpressing Breast Cancer Cells
P2860
Q30358195-1FC12940-382F-475E-BB54-208057586272Q34256302-AC6BD5BA-3DFB-4573-ADE0-A71A255545BAQ35207269-E605526A-72A9-461A-8012-DC009F3A3A47Q36564480-DB9D0C7F-7DD1-4C49-979F-FBD458E3212AQ36653978-D5C5DEDC-A610-427F-8C8B-22BCF152EAE9Q36715569-3F46F84B-3583-407D-9B33-0A79D035D28BQ36838995-1B1EC936-7971-4ECA-A3C8-869EB3100717Q37623841-C13307B0-EE2E-4C27-8FE5-B0290B6FCB73Q38086377-B43578D6-9DFB-4EF4-9378-FC989E4F82AAQ38832093-B64E6B99-7E5B-40EF-9560-41CCA127E50BQ39306543-9114C9FF-AAF0-4AC8-B059-99B5B3F5C663Q42429773-84B0BC4E-6216-4821-81D9-75828757FE32Q55716317-BDE19C01-4056-472D-AC5F-C140AB17F99FQ57125902-90B86610-A923-4898-B652-3D089CE4498F
P2860
Docetaxel immunonanocarriers as targeted delivery systems for HER 2-positive tumor cells: preparation, characterization, and cytotoxicity studies
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Docetaxel immunonanocarriers a ...... tion, and cytotoxicity studies
@ast
Docetaxel immunonanocarriers a ...... tion, and cytotoxicity studies
@en
type
label
Docetaxel immunonanocarriers a ...... tion, and cytotoxicity studies
@ast
Docetaxel immunonanocarriers a ...... tion, and cytotoxicity studies
@en
prefLabel
Docetaxel immunonanocarriers a ...... tion, and cytotoxicity studies
@ast
Docetaxel immunonanocarriers a ...... tion, and cytotoxicity studies
@en
P2093
P2860
P356
P1476
Docetaxel immunonanocarriers a ...... tion, and cytotoxicity studies
@en
P2093
Hojatollah Rabbani
Mohsen Amini
Mona Noori Koopaei
Rassoul Dinarvand
Seyed Nasser Ostad
Shaghayegh Emami
P2860
P304
P356
10.2147/IJN.S23211
P407
P577
2011-09-08T00:00:00Z